NEtPhOH-THPI

NEtPhOH-THPI, also known as N′-(2-methoxyphenylethyl)-THPI, is a serotonin 5-HT 2 receptor agonist and possible serotonergic psychedelic of the tetrahydropyridinylindole (THPI) family related to psychedelic tryptamines.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 4 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

NEtPhOH-THPI, also known as N′-(2-methoxyphenylethyl)-THPI, is a serotonin 5-HT 2 receptor agonist and possible serotonergic psychedelic of the tetrahydropyridinylindole (THPI) family related to psychedelic tryptamines. It is a cyclized tryptamine with an NBOMe-like substitution. The drug is a potent and high-efficacy partial agonist of the serotonin 5-HT 2A receptor.

Its affinity (K i ) for the receptor was 8.58 nM and its and values were 20.7 nM (66.5%) for G q signaling and 58.4 nM (80.7%) for β-arrestin2 signaling. NEtPhOH-THPI is also a potent near-full agonist of the serotonin 5-HT 2B receptor ( = 7.94 nM; = 88.9%) and a lower-potency full agonist of the serotonin 5-HT 2C receptor ( = 263 nM; = 105.1%).

It is a weak serotonin reuptake inhibitor ( = 1,288 nM) as well. NEtPhOH-THPI induced the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It produced the head-twitch response at a dose of 3 mg/kg in mice but not at a dose of 1 mg/kg or 10 mg/kg.

The drug produced about half the maximal number of head twitches as LSD. The preclinical pharmacokinetics of NEtPhOH-THPI via intraperitoneal injection have been studied. NEtPhOH-THPI was first described in the scientific literature by Rongyan Li and colleagues by 2025.

A close non-hallucinogenic pyrrolopyridine analogue with antidepressant-like effects in rodents was also reported.…

NEtPhOH-THPI, also known as N′-(2-methoxyphenylethyl)-THPI, is a serotonin 5-HT 2 receptor agonist and possible serotonergic psychedelic of the tetrahydropyridinylindole (THPI) family related to psychedelic tryptamines. It is a cyclized tryptamine with an NBOMe-like substitution. The drug is a potent and high-efficacy partial agonist of the serotonin 5-HT 2A receptor.

Its affinity (K i ) for the receptor was 8.58 nM and its and values were 20.7 nM (66.5%) for G q signaling and 58.4 nM (80.7%) for β-arrestin2 signaling. NEtPhOH-THPI is also a potent near-full agonist of the serotonin 5-HT 2B receptor ( = 7.94 nM; = 88.9%) and a lower-potency full agonist of the serotonin 5-HT 2C receptor ( = 263 nM; = 105.1%).

It is a weak serotonin reuptake inhibitor ( = 1,288 nM) as well. NEtPhOH-THPI induced the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It produced the head-twitch response at a dose of 3 mg/kg in mice but not at a dose of 1 mg/kg or 10 mg/kg.

The drug produced about half the maximal number of head twitches as LSD. The preclinical pharmacokinetics of NEtPhOH-THPI via intraperitoneal injection have been studied. NEtPhOH-THPI was first described in the scientific literature by Rongyan Li and colleagues by 2025.

A close non-hallucinogenic pyrrolopyridine analogue with antidepressant-like effects in rodents was also reported. The chemical syntheses of both this compound and NEtPhOH-THPI were described.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378570422 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.